年轻真性红细胞增多症患者的降细胞治疗:安全性与结局的荟萃分析
该系统综述与荟萃分析检索多个数据库后纳入14项研究,评估年龄<60岁真性红细胞增多症(PV<60)患者接受干扰素α(rIFN-α)或羟基脲(HU)治疗的毒性与疾病相关并发症。rIFN-α组加权平均年龄48岁(n=744,12项研究),HU组56岁(n=1397,8项研究);两种药物加权平均治疗时长均为4.5年。rIFN-α因毒性停药合并年发生率5.2%(n=587,95%CI 2.2-8.2),HU为3.6%(n=1097,95%CI 1-6.2);作者认为降细胞治疗尤其疾病修饰性rIFN-α可能使PV<60患者获益,未来需优先纳入PV<60患者的随机试验。
要点
- rIFN-α组因毒性停药合并年发生率为5.2%(n=587,95%CI 2.2-8.2),HU组为3.6%(n=1097,95%CI 1-6.2)。
- rIFN-α与HU的平均完全血液学缓解率分别为62%和52%。
- rIFN-α组与HU组血栓事件合并年发生率分别为0.79%和1.26%,继发性骨髓纤维化分别为1.06%和1.62%。
核心结论
- 在非致死性毒性发生率可接受的前提下,降细胞治疗尤其疾病修饰性rIFN-α可能使年龄<60岁真性红细胞增多症患者获益。
- 未来需开展优先纳入年龄<60岁真性红细胞增多症患者的随机试验,以确立早期降细胞治疗的长期获益。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus、Web of Science和Embase,初检693篇唯一文献,最终纳入14项符合标准的研究进行分析。
- 采用贝叶斯分层模型合并分析年龄<60岁真性红细胞增多症患者接受rIFN-α或羟基脲治疗的毒性与疾病相关并发症。
- rIFN-α组加权平均年龄48岁(n=744,12项研究),羟基脲组加权平均年龄56岁(n=1397,8项研究)。
- 两种药物的加权平均治疗时长均为4.5年。
主要发现
- rIFN-α因毒性停药合并年发生率为5.2%(n=587,95%CI 2.2-8.2),羟基脲为3.6%(n=1097,95%CI 1-6.2)。
- rIFN-α与羟基脲的平均完全血液学缓解率分别为62%和52%。
- rIFN-α组与羟基脲组血栓事件合并年发生率分别为0.79%和1.26%,继发性骨髓纤维化分别为1.06%和1.62%。
- rIFN-α组与羟基脲组急性髓系白血病合并年发生率分别为0.14%和0.26%,死亡分别为0.87%和2.65%。
- 未报告治疗相关死亡。
关键数值与推荐
- rIFN-α因毒性停药合并年发生率5.2%(n=587,95%CI 2.2-8.2)。
- 羟基脲因毒性停药合并年发生率3.6%(n=1097,95%CI 1-6.2)。
- rIFN-α平均完全血液学缓解率62%,羟基脲52%。
- rIFN-α与羟基脲血栓事件合并年发生率分别为0.79%和1.26%,继发性骨髓纤维化分别为1.06%和1.62%。
- rIFN-α与羟基脲急性髓系白血病合并年发生率分别为0.14%和0.26%,死亡分别为0.87%和2.65%。
临床怎么用
- 原文结论指出,在非致死性毒性发生率可接受的前提下,降细胞治疗尤其疾病修饰性rIFN-α可能使年龄<60岁真性红细胞增多症患者获益。
- 原文未据此给出具体推荐。
局限性
- 未来需开展优先纳入年龄<60岁真性红细胞增多症患者的随机试验,以确立早期降细胞治疗的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data support this approach. To support objective risk/benefit assessment of cytoreductive drugs in patients with PV aged <60 years (PV<60), this systematic review and meta-analysis was conducted to evaluate toxicity and disease-related complications in PV<60 treated with interferon alfa (rIFN-α) or hydroxyurea (HU). A search of PubMed, Scopus, Web of Science and Embase identified 693 unique studies with relevant keywords, of which 14 met inclusion criteria and were selected for analysis. The weighted average age of patients treated with rIFN-α was 48 years (n = 744 patients; 12 studies) and for HU was 56 years (n = 1397; 8 studies). The weighted average duration of treatment for either drug was 4.5 years. Using a Bayesian hierarchical model, the pooled annual rate of discontinuation due to toxicity was 5.2% for patients receiving rIFN-α (n = 587; 95% confidence interval [CI], 2.2-8.2) and 3.6% for HU (n = 1097; CI, 1-6.2). The average complete hematologic response for rIFN-α and HU was 62% and 52%, respectively. Patients experienced thrombotic events at a pooled annual rate of 0.79% and 1.26%; secondary myelofibrosis at 1.06% and 1.62%; acute myeloid leukemia at 0.14% and 0.26%; and death at 0.87% and 2.65%, respectively. No treatment-related deaths were reported. With acceptable rates of nonfatal toxicity, cytoreductive treatment, particularly with disease-modifying rIFN-α, may benefit PV<60. Future randomized trials prioritizing inclusion of PV<60 are needed to establish a long-term benefit of early cytoreductive treatment in these patients.
引用
- Chamseddine RS, Savenkov O, Rana S, et al. Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes. Blood Adv. 2024. PMID: 38507746. doi:10.1182/bloodadvances.2023012459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。